Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.

Abstract:

:Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete responses in 11%. When bendamustine 50 to 60 mg/m(2) was given on days 1 through 5, the overall response rate was 82.5%, with 14.5% complete responses. Bendamustine shows only partial cross-resistance with other agents used in the treatment of NHL and combination regimens have been investigated. The combination of bendamustine/vincristine/prednisolone (BOP) has been compared with cyclophosphamide/vincristine/prednisolone (COP) in a phase III study involving 162 patients with low-grade NHL. No differences were seen between the treatment arms with regard to response rate or survival, but the BOP regimen was significantly better tolerated than the COP regimen. The combination of rituximab/bendamustine has shown encouraging activity in patients with relapsed/refractory NHL and a trial is ongoing in which this combination is used in patients with advanced low-grade NHL or mantle cell lymphoma. Preliminary results from this trial are presented. The 93% overall response rate attained in the patients presently evaluable indicates that this combination is very active in this poor-prognosis population. Optimal treatment regimens with bendamustine in the treatment of low-grade NHL are yet to be defined, but results obtained to date indicate that further studies are warranted.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Rummel MJ,Mitrou PS,Hoelzer D

doi

10.1053/sonc.2002.34877

subject

Has Abstract

pub_date

2002-08-01 00:00:00

pages

27-32

issue

4 Suppl 13

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(02)90012-6

journal_volume

29

pub_type

杂志文章,评审
  • Moving disease biology from the laboratory to the clinic.

    abstract::To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34072

    authors: Anderson KC

    更新日期:2002-12-01 00:00:00

  • Genetics and ovarian carcinoma.

    abstract::Ovarian cancer is a disease that will affect approximately 1% of American women during their lifetime, and contributes to more than 14,000 deaths annually. If not detected early, this disease has a 5-year survival rate of less than 20%. Ovarian cancer develops predominantly from the malignant transformation of a singl...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Lynch HT,Casey MJ,Lynch J,White TE,Godwin AK

    更新日期:1998-06-01 00:00:00

  • Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery.

    abstract::During the past decade, local control of primary sarcomas of the extremities by radiation and conservative surgery has supplanted more radical compartmental resections or amputations. Reviews of others and our published data show that the probability of achieving local control is highly dependent on achieving negative...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Spiro IJ,Gebhardt MC,Jennings LC,Mankin HJ,Harmon DC,Suit HD

    更新日期:1997-10-01 00:00:00

  • The interface between medical oncology and supportive and palliative cancer care.

    abstract::Traditionally, medical oncology has focused on the active period of diagnosis, treatment and follow-up of cancer patients, and palliative medicine, the pre-terminal and end-of-life phases. Palliative medicine physicians have particular expertise in communication and symptom control, especially, for example, with pain ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2011.03.021

    authors: Storey DJ,Fallon MT,Smyth JF

    更新日期:2011-06-01 00:00:00

  • Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

    abstract::Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.09.017

    authors: Simone CB 2nd,Cengel KA

    更新日期:2014-12-01 00:00:00

  • Hepatic arterial chemotherapy in metastatic colorectal patients.

    abstract::Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kemeny NE,Ron IG

    更新日期:1999-10-01 00:00:00

  • Recent developments in breast cancer therapy.

    abstract::Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hortobagyi GN,Hung MC,Buzdar AU

    更新日期:1999-08-01 00:00:00

  • Reirradiation of recurrent head and neck cancers with curative intent.

    abstract::In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.003

    authors: Chmura SJ,Milano MT,Haraf DJ

    更新日期:2004-12-01 00:00:00

  • Pathologic prognostic factors in esophageal carcinoma.

    abstract::Thus, many interesting and promising techniques are now available for the study of potential prognostic factors in esophageal carcinoma, and the results may supplement the information that is obtained by routine histopathologic analysis. It may become possible to define subgroups of patients with lower risk tumors, fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Klimstra DS

    更新日期:1994-08-01 00:00:00

  • Paclitaxel pharmacokinetics and pharmacodynamics.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kearns CM,Gianni L,Egorin MJ

    更新日期:1995-06-01 00:00:00

  • Sarcoma in the young adult population: an international view.

    abstract::The outcomes in young adults aged 20-39 with sarcoma tend to be inferior compared to those in children and adolescents. There are differences in sarcoma histotype distribution with age, such that pediatric-type tumors predominate in the 20- to 25-year-old group while more adult-type sarcomas occur in those aged 35-39 ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.03.006

    authors: Soliman H,Ferrari A,Thomas D

    更新日期:2009-06-01 00:00:00

  • Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

    更新日期:1995-08-01 00:00:00

  • Psychosocial and sexual functioning of survivors of breast cancer.

    abstract::The literature documents that the majority of breast cancer survivors have adjusted well after their first 2 years since diagnosis. However, there is a subset of survivors reporting psychological distress, including depression and anxiety, involving approximately 30% by 4 years post-treatment, but widely ranging from ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.08.025

    authors: Kornblith AB,Ligibel J

    更新日期:2003-12-01 00:00:00

  • Pathological and molecular assessment of sentinel lymph nodes in solid tumors.

    abstract::Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.32894

    authors: Krag DN,Weaver DL

    更新日期:2002-06-01 00:00:00

  • Are sex discordant outcomes in COVID-19 related to sex hormones?

    abstract::COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.06.002

    authors: Strope JD,Chau CH,Figg WD

    更新日期:2020-10-01 00:00:00

  • Treatment of cancer-related hypercalcemia.

    abstract::Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ritch PS

    更新日期:1990-04-01 00:00:00

  • The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia.

    abstract::Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The time of its onset appears to be a random phenomenon, varying from a probable coincidence occurrence with the onset of CML to more than a decade after onset of the chronic phase. In most patients the diagnosis is obvious as v...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Boggs DR

    更新日期:1976-09-01 00:00:00

  • Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

    abstract::A dose-finding study was set up to identify the optimal dose of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin for phase II studies in patients with advanced chemotherapy-naive non-small cell lung cancer (NSCLC). The influence of drug sequence on the toxicity and pha...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Giaccone G,Huizing M,Postmus PE,ten Bokkel Huinink WW,Koolen M,van Zandwijk N,Vermorken JB,Beijnen JH,Dalesio O,Pinedo HM

    更新日期:1995-08-01 00:00:00

  • Novel strategies for the early detection and prevention of lung cancer.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.02.009

    authors: Wardwell NR,Massion PP

    更新日期:2005-06-01 00:00:00

  • Is there a place for "dose-dense" weekly schedules of the taxoids?

    abstract::The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Löffler TM

    更新日期:1998-10-01 00:00:00

  • Strategies in the development of recombinant vaccines for colon cancer.

    abstract::A new era involving the evaluation of recombinant vaccines for colon cancer has begun with the concurrent emergence of insights and technologies in the fields of molecular biology and immunology. These advances include (I) the identification and cloning of an array of genes associated with the neoplastic process, such...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schlom J,Tsang KY,Kantor JA,Abrams SI,Zaremba S,Greiner J,Hodge JW

    更新日期:1999-12-01 00:00:00

  • Epidemiology of acute myelogenous leukemia.

    abstract::The epidemiologic literature suggests that environmental exposures, familial susceptibility, and cytogenetic changes affect AML risk in childhood and adulthood. Unfortunately, many studies are limited by inadequate sample sizes, imprecise case definition, or inadequate exposure measurement. Few studies have singled ou...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sandler DP

    更新日期:1987-12-01 00:00:00

  • Small cell carcinoma of the lung: cellular origin and relationship to other neoplasms.

    abstract::Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tischler AS

    更新日期:1978-09-01 00:00:00

  • Adjuvant therapy for gastric cancer.

    abstract::The curative management of gastric adenocarcinoma depends on complete resection of the primary tumor. In patients with lymph node metastases in the resected specimen, the relapse and death rates from recurrent cancer are 70% to 80%. There is continued debate over whether more extensive lymph node dissection (D2) impro...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00298-7

    authors: Macdonald JS

    更新日期:2003-08-01 00:00:00

  • Small cell carcinoma of the head and neck: a review.

    abstract::Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.024

    authors: Renner G

    更新日期:2007-02-01 00:00:00

  • Gemcitabine/carboplatin in advanced urothelial cancer.

    abstract::Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2001.22537

    authors: Carles J,Nogué M

    更新日期:2001-06-01 00:00:00

  • Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

    abstract::Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31524

    authors: Arteaga CL,Khuri F,Krystal G,Sebti S

    更新日期:2002-02-01 00:00:00

  • Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.

    abstract::A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

    更新日期:1990-12-01 00:00:00

  • Developments in therapy for extensive-disease small cell lung cancer.

    abstract::Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Comis RL

    更新日期:1992-12-01 00:00:00

  • Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 1-hour infusion potentially offers its recipients reduced toxicity, demonstrated efficacy, and greater ease of administration. To confirm this hypothesis, we undertook a phase I/II study of 1-hour, single-agent paclitaxel in 164 patients' refra...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hainsworth JD,Greco FA

    更新日期:1995-12-01 00:00:00